Dermatan Sulfate Released after Injury Is a Potent Promoter of Fibroblast Growth Factor-2 Function

• DOI: 10.1074/jbc.273.43.28116
• Publication Date: 2002-07-26T15:02:22Z
• Authors: Stanley F. Penc; Bohdan Pomahac; Thomas Winkler; Robert A. Dorschner; Elof Eriksson; Mary Herndon; Richard L. Gallo
• Keywords: Wound Healing; 0303 health sciences; Dose-Response Relationship, Drug; Dermatan Sulfate; Wounds, Penetrating; Body Fluids; 3. Good health; 03 medical and health sciences; Humans; Female; Fibroblast Growth Factor 2; Cell Division; Mastectomy; Neck

Proteoglycans have been shown in vitro to bind multiple components of the cellular microenvironment that function during wound healing. To study the composition and function of these molecules when derived from an in vivo source, soluble proteoglycans released into human wound fluid were characterized and evaluated for influence on fibroblast growth factor-2 activity. Immunoblot analysis of wound fluid revealed the presence of syndecan-1, syndecan-4, glypican, decorin, perlecan, and versican. Sulfated glycosaminoglycan concentrations ranged from 15 to 65 microgram/ml, and treatment with chondroitinase B showed that a large proportion of the glycosaminoglycan was dermatan sulfate. The total glycosaminoglycan mixture present in wound fluid supported the ability of fibroblast growth factor-2 to signal cell proliferation. Dermatan sulfate, and not heparan sulfate, was the major contributor to this activity, and dermatan sulfate bound FGF-2 with Kd = 2.48 microM. These data demonstrate that proteoglycans released during wound repair are functionally active and provide the first evidence that dermatan sulfate is a potent mediator of fibroblast growth factor-2 responsiveness.